PL1912626T3 - Postaci użytkowe o polepszonej biodostępności - Google Patents
Postaci użytkowe o polepszonej biodostępnościInfo
- Publication number
- PL1912626T3 PL1912626T3 PL06776679.0T PL06776679T PL1912626T3 PL 1912626 T3 PL1912626 T3 PL 1912626T3 PL 06776679 T PL06776679 T PL 06776679T PL 1912626 T3 PL1912626 T3 PL 1912626T3
- Authority
- PL
- Poland
- Prior art keywords
- dosage forms
- improved bioavailability
- bioavailability
- improved
- dosage
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59581805P | 2005-08-08 | 2005-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1912626T3 true PL1912626T3 (pl) | 2016-10-31 |
Family
ID=37122088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06776679.0T PL1912626T3 (pl) | 2005-08-08 | 2006-08-08 | Postaci użytkowe o polepszonej biodostępności |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20090028938A1 (pl) |
| EP (1) | EP1912626B1 (pl) |
| JP (1) | JP2009504590A (pl) |
| CA (1) | CA2618264C (pl) |
| DK (1) | DK1912626T3 (pl) |
| ES (1) | ES2576633T3 (pl) |
| PL (1) | PL1912626T3 (pl) |
| PT (1) | PT1912626T (pl) |
| WO (1) | WO2007017249A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| WO2006080029A1 (en) | 2005-01-27 | 2006-08-03 | Alembic Limited | Extended release formulation of levetiracetam |
| JP5243247B2 (ja) * | 2005-07-28 | 2013-07-24 | アイエスピー インヴェストメンツ インコーポレイテッド | スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品 |
| US8486456B2 (en) | 2005-08-08 | 2013-07-16 | Abbott Gmbh & Co., Kg | Itraconazole compositions with improved bioavailability |
| CN101702878B (zh) * | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 可溶性差的药物的药物组合物 |
| AR069539A1 (es) * | 2007-07-25 | 2010-02-03 | Tibotec Pharm Ltd | Avances respecto de las formulaciones de comprimidos contra el vih |
| EP2257279B1 (en) * | 2008-02-28 | 2016-08-17 | AbbVie Inc. | Preparation of tablets |
| EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
| US20140024723A1 (en) * | 2012-07-17 | 2014-01-23 | Dow Global Technologies Llc | Composition comprising an organic liquid diluent and a specific hydroxypropyl methylcellulose |
| CN104603194B (zh) | 2012-07-17 | 2017-11-24 | 陶氏环球技术有限责任公司 | 包含有机液体稀释剂和低粘度纤维素醚的组合物 |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US9980946B1 (en) * | 2017-01-25 | 2018-05-29 | Effcon Laboratories, Inc. | Extended release methazolamide formulation |
| EP3823607A4 (en) | 2018-07-19 | 2022-04-06 | Impel NeuroPharma Inc. | ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE |
| JP2025536556A (ja) | 2022-10-25 | 2025-11-07 | ヴェラダーミクス インコーポレイテッド | 放出調節ミノキシジル用組成物および使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| DE3612211A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
| DE3812567A1 (de) * | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
| ES2158859T3 (es) | 1992-03-18 | 2001-09-16 | Janssen Pharmaceutica Nv | Estereoisomeros itraconazol y saperconazol. |
| TR199800729T2 (xx) * | 1995-11-23 | 1998-07-21 | Janssen Pharmaceutica N.V. | Eritmeli ekstr�zyonla haz�rlanan siklodekstrin kat� kar���mlar�. |
| KR19990044257A (ko) * | 1996-05-20 | 1999-06-25 | 디르크 반테 | 생체이용율이 개선된 항진균성 조성물 |
| PL340305A1 (en) * | 1997-11-03 | 2001-01-29 | Janssen Pharmaceutica Nv | Composition of agents reducing the level of lipoides |
| DE10046541A1 (de) * | 2000-09-19 | 2002-03-28 | Knoll Ag | Mechanisch stabile darreichungsformen, enthaltend Ubichinone |
| EP1323416B1 (en) * | 2000-09-25 | 2010-12-22 | Nippon Shinyaku Co., Ltd. | Process for producing medicinal solid dispersion |
| RU2356549C2 (ru) * | 2002-12-17 | 2009-05-27 | Эббетт ГмбХ унд Ко.КГ | Композиция, включающая фенофибриновую кислоту, ее физиологически приемлемую соль или производное |
| EP1581210B1 (en) * | 2002-12-20 | 2008-03-19 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8486456B2 (en) * | 2005-08-08 | 2013-07-16 | Abbott Gmbh & Co., Kg | Itraconazole compositions with improved bioavailability |
-
2006
- 2006-08-08 PL PL06776679.0T patent/PL1912626T3/pl unknown
- 2006-08-08 DK DK06776679.0T patent/DK1912626T3/en active
- 2006-08-08 US US11/997,325 patent/US20090028938A1/en not_active Abandoned
- 2006-08-08 EP EP06776679.0A patent/EP1912626B1/en active Active
- 2006-08-08 WO PCT/EP2006/007840 patent/WO2007017249A1/en not_active Ceased
- 2006-08-08 CA CA2618264A patent/CA2618264C/en active Active
- 2006-08-08 PT PT67766790T patent/PT1912626T/pt unknown
- 2006-08-08 ES ES06776679.0T patent/ES2576633T3/es active Active
- 2006-08-08 JP JP2008525468A patent/JP2009504590A/ja active Pending
-
2011
- 2011-06-21 US US13/165,398 patent/US9060936B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9060936B2 (en) | 2015-06-23 |
| EP1912626A1 (en) | 2008-04-23 |
| CA2618264C (en) | 2015-11-24 |
| US20110311595A1 (en) | 2011-12-22 |
| EP1912626B1 (en) | 2016-04-13 |
| DK1912626T3 (en) | 2016-08-01 |
| US20090028938A1 (en) | 2009-01-29 |
| PT1912626T (pt) | 2016-07-20 |
| WO2007017249A1 (en) | 2007-02-15 |
| ES2576633T3 (es) | 2016-07-08 |
| JP2009504590A (ja) | 2009-02-05 |
| CA2618264A1 (en) | 2007-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251539A0 (en) | Single pharmaceutical dosage form | |
| GB0501999D0 (en) | Pharmaceutical compounds | |
| GB0520657D0 (en) | Pharmaceutical compounds | |
| IL184858A0 (en) | Alcohol resistant dosage forms | |
| GB0508306D0 (en) | Nicotine dosage forms | |
| GB0520656D0 (en) | Pharmaceutical compounds | |
| IL188438A0 (en) | New pharmaceutical compounds | |
| AP2008004533A0 (en) | Pharmaceutical combination | |
| GB0427455D0 (en) | Dosage forms | |
| PL1912626T3 (pl) | Postaci użytkowe o polepszonej biodostępności | |
| GB0423964D0 (en) | Dosage form | |
| GB0513984D0 (en) | Dosage form | |
| ZA200804666B (en) | Pharmaceutical combination | |
| GB0512643D0 (en) | Pharmaceutical compounds | |
| ZA200705612B (en) | Pharmaceutical compounds | |
| TWI372053B (en) | Combination drug | |
| GB0512246D0 (en) | Novel pharmaceutical | |
| GB0501475D0 (en) | Pharmaceutical compounds | |
| GB0522989D0 (en) | Dosage form | |
| GB0516790D0 (en) | Pharmaceutical compounds | |
| GB0516167D0 (en) | Pharmaceutical compounds | |
| GB0512654D0 (en) | Pharmaceutical compounds | |
| GB0526607D0 (en) | Pharmaceutical compounds | |
| GB0512642D0 (en) | Pharmaceutical compounds | |
| GB0510252D0 (en) | Pharmaceutical compounds |